https://stock.noler.com/us/stock/acceleron-pharma-inc https://stock.noler.com/us/stock/acceleron-pharma-inc/accounts-payable https://stock.noler.com/us/stock/acceleron-pharma-inc/accounts-receivable https://stock.noler.com/us/stock/acceleron-pharma-inc/accounts-receivable-related-parties-current https://stock.noler.com/us/stock/acceleron-pharma-inc/accretion-amortization-of-discounts-and-premiums-investments https://stock.noler.com/us/stock/acceleron-pharma-inc/accretion-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/accrual-provision https://stock.noler.com/us/stock/acceleron-pharma-inc/accrued-income-taxes-current https://stock.noler.com/us/stock/acceleron-pharma-inc/accrued-liabilities-current https://stock.noler.com/us/stock/acceleron-pharma-inc/accrued-professional-fees-current https://stock.noler.com/us/stock/acceleron-pharma-inc/accrued-royalties-current-and-noncurrent https://stock.noler.com/us/stock/acceleron-pharma-inc/accumulated-depreciation https://stock.noler.com/us/stock/acceleron-pharma-inc/activist-13d-13g-form-sc-13d https://stock.noler.com/us/stock/acceleron-pharma-inc/activist-13d-13g-form-sc-13g https://stock.noler.com/us/stock/acceleron-pharma-inc/additional-paid-in-capital https://stock.noler.com/us/stock/acceleron-pharma-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/allowance-for-doubtful-accounts-receivable https://stock.noler.com/us/stock/acceleron-pharma-inc/amended-reports-10-q https://stock.noler.com/us/stock/acceleron-pharma-inc/amortization-of-debt-discount-premium https://stock.noler.com/us/stock/acceleron-pharma-inc/amortization-of-financing-costs https://stock.noler.com/us/stock/acceleron-pharma-inc/amortization-of-financing-costs-and-discounts https://stock.noler.com/us/stock/acceleron-pharma-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/acceleron-pharma-inc/aoci https://stock.noler.com/us/stock/acceleron-pharma-inc/assets-fair-value-disclosure https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-accumulated-gross-unrealized-gain-before-tax https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-amortized-cost https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-debt-accumulated-gross-unrealized-gain-before-tax https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-debt-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-debt-amortized-cost-basis https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-debt-securities https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-debt-unrealized-loss-position https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-debt-unrealized-loss-position-12-months-or-longer https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-debt-unrealized-loss-position-12-months-or-longer-loss https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-debt-unrealized-loss-position-12-months-or-longer-number-of-positions https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-debt-unrealized-loss-position-less-than-12-months https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-debt-unrealized-loss-position-number-of-positions https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-gross-realized-gain-loss-net https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-securities https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-unrealized-loss-position-12-months-or-longer-aggregate-losses https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-unrealized-loss-position-12-months-or-longer-loss https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-unrealized-loss-position-fair-value https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-unrealized-loss-position-less-than-twelve-months-fair-value https://stock.noler.com/us/stock/acceleron-pharma-inc/available-for-sale-unrealized-loss-position-twelve-months-or-longer-fair-value https://stock.noler.com/us/stock/acceleron-pharma-inc/basic-shares https://stock.noler.com/us/stock/acceleron-pharma-inc/buybacks-payments-for-repurchase-of-equity https://stock.noler.com/us/stock/acceleron-pharma-inc/buybacks-shares-repurchased-value https://stock.noler.com/us/stock/acceleron-pharma-inc/capital-expenditures https://stock.noler.com/us/stock/acceleron-pharma-inc/capital-expenditures-incurred-but-not-yet-paid https://stock.noler.com/us/stock/acceleron-pharma-inc/cash-and-cash-equivalents-change https://stock.noler.com/us/stock/acceleron-pharma-inc/cash-and-equivalents https://stock.noler.com/us/stock/acceleron-pharma-inc/cash-and-restricted-cash https://stock.noler.com/us/stock/acceleron-pharma-inc/cash-flow-breakdown https://stock.noler.com/us/stock/acceleron-pharma-inc/class-of-warrant-or-right-exercise-price-of-warrants-or-rights https://stock.noler.com/us/stock/acceleron-pharma-inc/class-of-warrant-or-right-exercise-price-of-warrants-or-rights-1 https://stock.noler.com/us/stock/acceleron-pharma-inc/class-of-warrant-or-right-number-of-securities-called-by-warrants-or-rights https://stock.noler.com/us/stock/acceleron-pharma-inc/commitments-and-contingencies https://stock.noler.com/us/stock/acceleron-pharma-inc/common-stock-capital-shares-reserved-for-future-issuance https://stock.noler.com/us/stock/acceleron-pharma-inc/common-stock-dividends-per-share-cash-paid https://stock.noler.com/us/stock/acceleron-pharma-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/acceleron-pharma-inc/common-stock-value https://stock.noler.com/us/stock/acceleron-pharma-inc/comprehensive-income https://stock.noler.com/us/stock/acceleron-pharma-inc/contract-liability https://stock.noler.com/us/stock/acceleron-pharma-inc/contract-revenue-cost https://stock.noler.com/us/stock/acceleron-pharma-inc/contract-with-customer-liability-change-in-timeframe-performance-obligation-satisfied-revenue-recognized https://stock.noler.com/us/stock/acceleron-pharma-inc/contract-with-customer-liability-noncurrent https://stock.noler.com/us/stock/acceleron-pharma-inc/contracts-revenue https://stock.noler.com/us/stock/acceleron-pharma-inc/conversion-of-stock-amount-converted https://stock.noler.com/us/stock/acceleron-pharma-inc/costs-and-expenses https://stock.noler.com/us/stock/acceleron-pharma-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/acceleron-pharma-inc/cumulative-effect-of-new-accounting-principle-in-period-of-adoption https://stock.noler.com/us/stock/acceleron-pharma-inc/current-assets https://stock.noler.com/us/stock/acceleron-pharma-inc/current-liabilities https://stock.noler.com/us/stock/acceleron-pharma-inc/current-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/acceleron-pharma-inc/debt-conversion-converted-instrument-amount https://stock.noler.com/us/stock/acceleron-pharma-inc/debt-periodic-payment-terms-balloon-payment-to-be-paid https://stock.noler.com/us/stock/acceleron-pharma-inc/debt-repaid https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-rent-credit-current https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-rent-credit-noncurrent https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-revenue https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-revenue-2 https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-revenue-noncurrent https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-tax-assets-deferred-income https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-tax-assets-net https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-tax-assets-operating-loss-carryforwards-subject-to-expiration https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-tax-assets-tax-credit-carryforwards-research https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-tax-assets-tax-deferred-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/acceleron-pharma-inc/deferred-tax-liabilities-leasing-arrangements https://stock.noler.com/us/stock/acceleron-pharma-inc/defined-contribution-plan-cost-recognized https://stock.noler.com/us/stock/acceleron-pharma-inc/depreciation-and-amortization https://stock.noler.com/us/stock/acceleron-pharma-inc/diluted-shares https://stock.noler.com/us/stock/acceleron-pharma-inc/dividends-per-share https://stock.noler.com/us/stock/acceleron-pharma-inc/due-from-related-parties-current https://stock.noler.com/us/stock/acceleron-pharma-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/acceleron-pharma-inc/effective-tax-rate https://stock.noler.com/us/stock/acceleron-pharma-inc/employee-benefits-and-share-based-compensation https://stock.noler.com/us/stock/acceleron-pharma-inc/employee-related-liabilities-current https://stock.noler.com/us/stock/acceleron-pharma-inc/eps https://stock.noler.com/us/stock/acceleron-pharma-inc/eps-basic https://stock.noler.com/us/stock/acceleron-pharma-inc/fair-value-adjustment-of-warrants https://stock.noler.com/us/stock/acceleron-pharma-inc/fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/acceleron-pharma-inc/fair-value-disclosure-offbalance-sheet-risks-amount-asset https://stock.noler.com/us/stock/acceleron-pharma-inc/fair-value-disclosure-offbalance-sheet-risks-amount-liability https://stock.noler.com/us/stock/acceleron-pharma-inc/fair-value-measurement-with-unobservable-inputs-reconciliations-recurring-basis-liability-value https://stock.noler.com/us/stock/acceleron-pharma-inc/finance-lease-principal-payments https://stock.noler.com/us/stock/acceleron-pharma-inc/financial-liabilities-fair-value-disclosure https://stock.noler.com/us/stock/acceleron-pharma-inc/financing-cash-flow https://stock.noler.com/us/stock/acceleron-pharma-inc/form-d-other https://stock.noler.com/us/stock/acceleron-pharma-inc/form-d-stocks https://stock.noler.com/us/stock/acceleron-pharma-inc/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/acceleron-pharma-inc/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/acceleron-pharma-inc/general-and-administrative-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/income-tax https://stock.noler.com/us/stock/acceleron-pharma-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/acceleron-pharma-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/acceleron-pharma-inc/increase-decrease-in-accounts-receivable-related-parties https://stock.noler.com/us/stock/acceleron-pharma-inc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/acceleron-pharma-inc/increase-decrease-in-contract-with-customer-liability https://stock.noler.com/us/stock/acceleron-pharma-inc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/acceleron-pharma-inc/increase-decrease-in-due-from-related-parties-current https://stock.noler.com/us/stock/acceleron-pharma-inc/increase-decrease-in-other-deferred-liability https://stock.noler.com/us/stock/acceleron-pharma-inc/increase-decrease-in-other-operating-capital-net https://stock.noler.com/us/stock/acceleron-pharma-inc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/acceleron-pharma-inc/increase-decrease-in-restricted-cash-for-operating-activities https://stock.noler.com/us/stock/acceleron-pharma-inc/increase-in-carrying-amount-of-redeemable-preferred-stock https://stock.noler.com/us/stock/acceleron-pharma-inc/insider-transactions-preferred https://stock.noler.com/us/stock/acceleron-pharma-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/acceleron-pharma-inc/insider-transactions-warrants https://stock.noler.com/us/stock/acceleron-pharma-inc/interest-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/interest-income-other https://stock.noler.com/us/stock/acceleron-pharma-inc/interest-paid-net https://stock.noler.com/us/stock/acceleron-pharma-inc/interest-receivable https://stock.noler.com/us/stock/acceleron-pharma-inc/interest-receivable-current https://stock.noler.com/us/stock/acceleron-pharma-inc/investing-cash-flow https://stock.noler.com/us/stock/acceleron-pharma-inc/investment-income-interest https://stock.noler.com/us/stock/acceleron-pharma-inc/lease-and-rental-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/lessee-operating-lease-discount-rate https://stock.noler.com/us/stock/acceleron-pharma-inc/lessee-operating-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/acceleron-pharma-inc/lessee-operating-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/acceleron-pharma-inc/level-3-liability-gain-loss-included-in-earnings https://stock.noler.com/us/stock/acceleron-pharma-inc/level-3-liability-settlements https://stock.noler.com/us/stock/acceleron-pharma-inc/litigation-reserve-current https://stock.noler.com/us/stock/acceleron-pharma-inc/litigation-settlement-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/long-term-investments https://stock.noler.com/us/stock/acceleron-pharma-inc/long-term-notes-payable https://stock.noler.com/us/stock/acceleron-pharma-inc/net-cash-from-financing-activities https://stock.noler.com/us/stock/acceleron-pharma-inc/net-cash-from-investing-activities https://stock.noler.com/us/stock/acceleron-pharma-inc/net-cash-from-operating-activities https://stock.noler.com/us/stock/acceleron-pharma-inc/net-change-in-cash https://stock.noler.com/us/stock/acceleron-pharma-inc/net-income https://stock.noler.com/us/stock/acceleron-pharma-inc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/acceleron-pharma-inc/net-income-loss-available-to-common-stockholders-diluted https://stock.noler.com/us/stock/acceleron-pharma-inc/notes-payable-current https://stock.noler.com/us/stock/acceleron-pharma-inc/notes-receivable-related-parties-noncurrent https://stock.noler.com/us/stock/acceleron-pharma-inc/number-of-operating-segments https://stock.noler.com/us/stock/acceleron-pharma-inc/oci-unrealized-holding-gain-loss-on-securities-arising-net-of-tax https://stock.noler.com/us/stock/acceleron-pharma-inc/oci-unrealized-holding-gain-loss-on-securities-arising-tax https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-cash-flow https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-income https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-assets https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-liability https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-liability-current https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-2 https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-after-year-five https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-future-minimum-sublease-rentals https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-year-five https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-year-four https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-leases-income-statement-sublease-revenue https://stock.noler.com/us/stock/acceleron-pharma-inc/operating-leases-rent-expense-net https://stock.noler.com/us/stock/acceleron-pharma-inc/other-accrued-liabilities-current https://stock.noler.com/us/stock/acceleron-pharma-inc/other-income https://stock.noler.com/us/stock/acceleron-pharma-inc/other-noncash-income-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/other-noncurrent-assets https://stock.noler.com/us/stock/acceleron-pharma-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/acceleron-pharma-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/other-prepaid-expense-current https://stock.noler.com/us/stock/acceleron-pharma-inc/paid-in-capital-share-based-compensation-stock-options-requisite-service-period-recognition https://stock.noler.com/us/stock/acceleron-pharma-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/acceleron-pharma-inc/payments-for-proceeds-from-tenant-allowance https://stock.noler.com/us/stock/acceleron-pharma-inc/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/acceleron-pharma-inc/payments-to-acquire-available-for-sale-securities https://stock.noler.com/us/stock/acceleron-pharma-inc/payments-to-acquire-marketable-securities https://stock.noler.com/us/stock/acceleron-pharma-inc/preferred-shares-facts https://stock.noler.com/us/stock/acceleron-pharma-inc/preferred-stock-discount-on-shares https://stock.noler.com/us/stock/acceleron-pharma-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/acceleron-pharma-inc/preferred-stock-redemption-discount https://stock.noler.com/us/stock/acceleron-pharma-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/acceleron-pharma-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/acceleron-pharma-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/acceleron-pharma-inc/preferred-stock-value https://stock.noler.com/us/stock/acceleron-pharma-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/acceleron-pharma-inc/pretax-income https://stock.noler.com/us/stock/acceleron-pharma-inc/pretax-income-minority-interest-and-income-loss-from-equity-method-investments https://stock.noler.com/us/stock/acceleron-pharma-inc/proceeds-from-debt-net-of-issuance-costs https://stock.noler.com/us/stock/acceleron-pharma-inc/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/acceleron-pharma-inc/proceeds-from-issuance-of-private-placement https://stock.noler.com/us/stock/acceleron-pharma-inc/proceeds-from-issuance-of-redeemable-convertible-preferred-stock https://stock.noler.com/us/stock/acceleron-pharma-inc/proceeds-from-issuance-of-shares-under-incentive-and-share-based-compensation-plans-including-stock-options https://stock.noler.com/us/stock/acceleron-pharma-inc/proceeds-from-sale-and-maturity-of-available-for-sale-securities https://stock.noler.com/us/stock/acceleron-pharma-inc/proceeds-from-sale-maturity-and-collections-of-investments https://stock.noler.com/us/stock/acceleron-pharma-inc/proceeds-from-sale-of-available-for-sale-securities https://stock.noler.com/us/stock/acceleron-pharma-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/acceleron-pharma-inc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/acceleron-pharma-inc/profit-loss https://stock.noler.com/us/stock/acceleron-pharma-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/acceleron-pharma-inc/property-plant-equipment https://stock.noler.com/us/stock/acceleron-pharma-inc/public-float https://stock.noler.com/us/stock/acceleron-pharma-inc/realized-gains-on-securities https://stock.noler.com/us/stock/acceleron-pharma-inc/reimbursement-revenue https://stock.noler.com/us/stock/acceleron-pharma-inc/repayments-of-long-term-capital-lease-obligations https://stock.noler.com/us/stock/acceleron-pharma-inc/research-and-development https://stock.noler.com/us/stock/acceleron-pharma-inc/restricted-cash-and-cash-equivalents https://stock.noler.com/us/stock/acceleron-pharma-inc/restricted-cash-and-cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/acceleron-pharma-inc/restricted-cash-equivalents-noncurrent https://stock.noler.com/us/stock/acceleron-pharma-inc/retained-earnings https://stock.noler.com/us/stock/acceleron-pharma-inc/revenue https://stock.noler.com/us/stock/acceleron-pharma-inc/revenue-from-contract-with-customer-excluding-assessed-tax https://stock.noler.com/us/stock/acceleron-pharma-inc/revenue-from-related-parties https://stock.noler.com/us/stock/acceleron-pharma-inc/sale-of-stock-consideration-received-on-transaction https://stock.noler.com/us/stock/acceleron-pharma-inc/sale-of-stock-number-of-shares-issued-in-transaction https://stock.noler.com/us/stock/acceleron-pharma-inc/sale-of-stock-price-per-share https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-comment-letters-corresp https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-comment-letters-drsltr https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-comment-letters-upload https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-10-k https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-10-q https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-15-12b https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-25-nse https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-8-a12b https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-8-k https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-ars https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-certnas https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-ct-order https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-def-14a https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-defa14a https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-regdex https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-sc-14d9 https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-sc-to-c https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-sc-to-t https://stock.noler.com/us/stock/acceleron-pharma-inc/sec-filings-sc14d9c https://stock.noler.com/us/stock/acceleron-pharma-inc/secondary-offerings-form-424b2 https://stock.noler.com/us/stock/acceleron-pharma-inc/secondary-offerings-form-424b4 https://stock.noler.com/us/stock/acceleron-pharma-inc/secondary-offerings-form-424b5 https://stock.noler.com/us/stock/acceleron-pharma-inc/secondary-offerings-form-drs https://stock.noler.com/us/stock/acceleron-pharma-inc/secondary-offerings-form-effect https://stock.noler.com/us/stock/acceleron-pharma-inc/secondary-offerings-form-s-1 https://stock.noler.com/us/stock/acceleron-pharma-inc/secondary-offerings-form-s-1mef https://stock.noler.com/us/stock/acceleron-pharma-inc/secondary-offerings-form-s-3asr https://stock.noler.com/us/stock/acceleron-pharma-inc/secondary-offerings-form-s-8 https://stock.noler.com/us/stock/acceleron-pharma-inc/sga-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/shareholders-equity https://stock.noler.com/us/stock/acceleron-pharma-inc/shares-authorized https://stock.noler.com/us/stock/acceleron-pharma-inc/shares-issued https://stock.noler.com/us/stock/acceleron-pharma-inc/shares-issued-price-per-share https://stock.noler.com/us/stock/acceleron-pharma-inc/short-term-investments https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-award-number-of-shares-available-for-grant https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-award-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-award-plan-modification-number-of-employees-affected https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-based-compensation https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-issued-shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-issued-shares-issued-value-espp https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-issued-shares-issued-value-restricted-stock-award-net-of-forfeitures https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-exercisable-number https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-exercises-in-period-total-intrinsic-value https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-forfeitures-and-expirations-in-period https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-forfeitures-and-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-forfeitures-in-period https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-outstanding-number https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-vested-and-expected-to-vest-outstanding-aggregate-intrinsic-value https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-vested-and-expected-to-vest-outstanding-average-exercise-price https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/acceleron-pharma-inc/stock-split-ratio https://stock.noler.com/us/stock/acceleron-pharma-inc/straight-line-rent https://stock.noler.com/us/stock/acceleron-pharma-inc/tangible-asset-impairment-charges https://stock.noler.com/us/stock/acceleron-pharma-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/acceleron-pharma-inc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/acceleron-pharma-inc/tax-rate-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/acceleron-pharma-inc/tax-rate-reconciliation-nondeductible-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/acceleron-pharma-inc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/acceleron-pharma-inc/tax-rate-reconciliation-tax-credits-research https://stock.noler.com/us/stock/acceleron-pharma-inc/tax-rate-reconciliation-tax-cuts-and-jobs-act-percent https://stock.noler.com/us/stock/acceleron-pharma-inc/tax-withholding-on-stock-awards https://stock.noler.com/us/stock/acceleron-pharma-inc/temporary-equity-accretion-to-redemption-value-adjustment https://stock.noler.com/us/stock/acceleron-pharma-inc/temporary-equity-carrying-amount-attributable-to-parent https://stock.noler.com/us/stock/acceleron-pharma-inc/temporary-equity-par-or-stated-value-per-share https://stock.noler.com/us/stock/acceleron-pharma-inc/temporary-equity-shares-authorized https://stock.noler.com/us/stock/acceleron-pharma-inc/total-assets https://stock.noler.com/us/stock/acceleron-pharma-inc/total-contract-liability https://stock.noler.com/us/stock/acceleron-pharma-inc/total-liabilities https://stock.noler.com/us/stock/acceleron-pharma-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/acceleron-pharma-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/acceleron-pharma-inc/utb-income-tax-penalties-accrued https://stock.noler.com/us/stock/acceleron-pharma-inc/utb-income-tax-penalties-and-interest-accrued https://stock.noler.com/us/stock/acceleron-pharma-inc/utb-income-tax-penalties-and-interest-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/utb-income-tax-penalties-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/utb-interest-on-income-taxes-accrued https://stock.noler.com/us/stock/acceleron-pharma-inc/utb-interest-on-income-taxes-expense https://stock.noler.com/us/stock/acceleron-pharma-inc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/acceleron-pharma-inc/warrants-and-rights-outstanding https://stock.noler.com/us/stock/acceleron-pharma-inc/weighted-average-number-of-share-outstanding-basic-and-diluted https://stock.noler.com/us/stock/acceleron-pharma-inc/weighted-average-number-of-shares-employee-stock-ownership-plan-shares-not-committed-to-be-released https://stock.noler.com/us/stock/acceleron-pharma-inc/weighted-average-number-of-shares-restricted-stock